NASDAQ · ANIP
ANI Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ANIP: Nov 05, 2026
ANI Pharmaceuticals, Inc. is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $1.8. The reported EPS for the same quarter last year was $1.64.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.80 | $1.90 | $1.66 | 4 |
| Dec 2026 | $2.43 | $2.58 | $2.15 | 4 |
| Mar 2027 | $1.15 | $1.28 | $1.03 | 2 |
| Jun 2027 | $1.97 | $2.05 | $1.89 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel- Zacks · Oct 29, 7:35 AM EDTNovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesNovoCure (NVCR) delivered earnings and revenue surprises of +57.14% and +5.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 19, 7:34 AM EDTANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules In 20, 30 And 60 Mg(RTTNews) – Monday, ANI Pharmaceuticals, Inc. (ANIP) announced the launch of Duloxetine Delayed-Release Capsules in 20, 30 and 60 mg, the generic version of the reference listed drug (RLD) Cymbalta.
- Zacks · Oct 13, 11:10 AM EDTWill ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks · Oct 13, 7:55 AM EDTThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarFinding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- RTTNews · Oct 12, 7:46 AM EDTANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study(RTTNews) – ANI Pharmaceuticals (ANIP) announced positive results from its Phase 4 SYNCHRONICITY trial evaluating the Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).
- Zacks · Oct 6, 7:55 AM EDTHow to Find Strong Medical Stocks Slated for Positive Earnings SurprisesFinding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- Zacks · Sep 28, 10:41 AM EDTImplied Volatility Surging for ANI Pharmaceuticals Stock OptionsInvestors need to pay close attention to ANIP stock based on the movements in the options market lately.
- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- Fintel · Sep 23, 4:01 PM EDTOppenheimer Initiates Coverage of ANI Pharmaceuticals with Perform RatingFintel reports that on September 23, 2026, Oppenheimer initiated coverage of ANI Pharmaceuticals (NASDAQGM:ANIP) (DB:BSFA) with a Perform recommendation.The stock recorded a pre-action close of $77.91 on September 22, 2026. The company's latest close was also recorded at $77.91 o
- RTTNews · Sep 23, 7:48 AM EDTANI Pharmaceuticals Wins FDA Approval For Generic Everolimus Tablets For Oral Suspension(RTTNews) – ANI Pharmaceuticals, Inc. (ANIP) announced that the U.S. FDA has approved its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product is the generic version of Afinitor Disperz.
- RTTNews · Sep 23, 7:20 AM EDTFDA Approves ANI Pharma's Generic Everolimus Tablets(RTTNews) – ANI Pharmaceuticals, Inc. (ANIP) said Wednesday that it received final FDA approval for Everolimus Tablets for Oral Suspension, a generic version of Novartis' Afinitor Disperz, which is approved for certain conditions associated with tuberous sclerosis complex (TSC).
- Zacks · Aug 14, 1:15 PM EDTShould You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for ANI Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.